Profitability Metrics

Gross Margin
26.76%
Operating Margin
11.59%
Net Margin
10.52%

Efficiency Metrics

Revenue per Expense Ratio
1.13
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
18.44%
Income Tax Rate
14.22%
EPS
2.1400000000

Balance Sheet Analysis

Current Ratio
1.47
Cash Ratio
0.61
Working Capital
$4.41B
Debt to Equity
0.64
Debt to Assets
27.29%
Equity Ratio
42.79%

Cash Flow Analysis

Operating Cash Flow Ratio
16.38%
Free Cash Flow Ratio
15.36%
CapEx to Revenue
1.02%
Dividends Paid
$750.37M
Stock Buybacks
$69.29M
Total Shareholder Returns
$819.66M
Cash Position Change
110.37%

Key Takeaways (2023 FY)

  • Revenue declined by 2.0442297674254%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes

Detailed Growth Metrics

Core Performance

Revenue
-2.04%
Net Income
103.13%
EPS
93.16%
Operating Income
152.06%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
52.34%
Operating Cash Flow
-9.84%
Free Cash Flow
12.05%

Balance Sheet Health

Assets
12.30%
Debt
20.29%
Book Value per Share
4.59%
Inventory
-10.33%

Shareholder Returns

Dividends per Share
-68.38%
Shares Outstanding
9.46%

Long Term Trends

3Y Revenue/Share
5.31%
5Y Revenue/Share
31.39%
3Y Dividend/Share
9.45%
5Y Dividend/Share
127.96%